Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study

Immunotherapy
Lisbeth BarkholtM S Dilber

Abstract

The chimeric state after allogeneic hematopoietic stem cell transplantation provides a platform for adoptive immunotherapy using donor-derived immune cells. The major risk with donor lymphocyte infusions (DLIs) is the development of graft-versus-host disease (GvHD). Development of new DLI products with antitumor reactivity and reduced GvHD risk represents a challenging task in cancer immunotherapy. Although natural killer (NK) and NK-like T cells are promising owing to their antitumor activity, their low concentrations in peripheral blood mononuclear cells reduces their utility in DLIs. We have recently developed a system that allows expansion of clinical-grade NK and NK-like T cells in large numbers. In this study, the safety of donor-derived long-term ex vivo-expanded human NK and NK-like T cells given as DLIs was investigated as immunotherapy for cancer in five patients following allogeneic stem cell infusion. Infusion of the cells was safe whether administered alone or with IL-2 subcutaneously. No signs of acute GvHD were observed. One patient with hepatocellular carcinoma showed markedly decreased serum alpha-fetoprotein levels following cell infusions. These findings suggest that the use of ex vivo-expanded NK and NK-like...Continue Reading

References

Jun 1, 1994·European Journal of Immunology·H WolfG Jung
Aug 31, 2002·Journal of Hematotherapy & Stem Cell Research·S CarlensM S Dilber
Feb 27, 2004·Cytotherapy·H-G Klingemann, J Martinson
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stefan W KrauseGabriele Multhoff
Mar 16, 2005·Current Opinion in Immunology·Loredana RuggeriAndrea Velardi
Jun 3, 2005·The Journal of Clinical Investigation·Daniel E Speiser, Pedro Romero
Jul 26, 2005·Cytotherapy·H-G Klingemann
Mar 23, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John K ChanRobert S Negrin
Apr 18, 2007·Nature Reviews. Immunology·Hans-Gustaf Ljunggren, Karl-Johan Malmberg
Jun 29, 2007·Nature Clinical Practice. Oncology·Ben SprangersAn D Billiau
Aug 3, 2007·Cancer Research·Matthias MatterAdrian F Ochsenbein
Nov 23, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·U S Kammula, F M Marincola

❮ Previous
Next ❯

Citations

Jun 19, 2012·Cellular & Molecular Immunology·Martha LuevanoAurore Saudemont
Mar 23, 2012·Nature Reviews. Immunology·Eric VivierLaurent Brossay
Oct 15, 2011·Immunotherapy·Anshu Malhotra, Anil Shanker
Jun 10, 2011·F1000 Medicine Reports·François Romagné, Eric Vivier
Jun 16, 2012·ISRN Oncology·Carolyn J TorkelsonLeanna J Standish
Nov 21, 2014·Immunopharmacology and Immunotoxicology·Xiao-Hong LiChun-Ji Gao
Mar 20, 2012·Leukemia & Lymphoma·James Godfrey, Don M Benson
Feb 18, 2016·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Letícia BaggioDean Anthony Lee
Mar 8, 2011·Cytotherapy·Tolga Sutlu, Evren Alici
Jun 8, 2012·Transfusion·Scott A KoepsellDavid H McKenna
May 5, 2011·Journal of Biomedicine & Biotechnology·Estrella Mariel LevyJosé Mordoh
Mar 12, 2015·Immunobiology·Qi LiQing-Sheng Huang
Jun 20, 2015·Frontiers in Immunology·Anna DomogalaAurore Saudemont
Mar 29, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yong-Xian HuHe Huang
Oct 5, 2010·Hematology/oncology and Stem Cell Therapy·Garnet Suck, Mickey Boon Chai Koh
Dec 17, 2014·Cancer Letters·Lakshmi Narendra BodduluruChandra Shaker Sriram
Jun 1, 2016·Frontiers in Immunology·Kamalakannan RajasekaranSubramaniam Malarkannan
Jul 20, 2016·Expert Opinion on Biological Therapy·Yi Lin, Hideho Okada
Sep 26, 2016·Blood Reviews·Geoffrey S KannanDean A Lee
Aug 30, 2017·International Journal of Molecular Sciences·Beatriz Martín-AntonioAlvaro Urbano-Ispizua
Apr 19, 2018·HLA : Immune Response Genetics·N Kumar, S I Khakoo
Nov 15, 2013·Expert Review of Hematology·Gösta Gahrton, Amrita Krishnan
Oct 17, 2019·Cancers·Sooyeon OhSang-Woon Choi
Mar 5, 2020·Cancer Immunology, Immunotherapy : CII·Raquel TarazonaRafael Solana
Feb 12, 2017·Cancer Immunology, Immunotherapy : CII·Zhongjuan WangHaiyan Liu
Dec 26, 2018·Expert Opinion on Biological Therapy·Kejian WangHuang Zhu
Feb 23, 2020·Frontiers in Immunology·Ece Canan SayitogluAdil Doganay Duru

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
flow cytometry
genotyping
ELISA
bronchoalveolar lavage
leukapheresis

Software Mentioned

Summit
Cell Quest

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.